Memo Therapeutics’ COVID-19 antibody on the fast track
News 14.08.2020 Swiss biotech company Memo Therapeutics AG (MTx) isolated a highly potent antibody isolated from clinically selected convalescent COVID-19 donors. The selected antibody will undergo an accelerated development program as an immunotherapy and for the prevention of COVID-19. MTx has already concluded a partnership for the production. MTx today announces a collaboration...